Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Abstract: The present invention is drawn to therapeutics which can target hnRNP A18, a regulator of protein translation in cancer cells. The invention provides a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition that decreases the level and/or activity of heterogenous ribonucleoprotein A18 (hnRNP A18). The composition can comprise a nucleic acid molecule that binds to at least a portion of a nucleotide sequence coding for hnRNP A18. The invention also provides a composition for treating cancer comprising a nucleic acid or antibody that is capable of decreasing the level and/or activity of hnRNP A18 and a pharmaceutically acceptable carrier. The invention also provides methods of screening for an anti-cancer compound.

Abstract: Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.

Abstract: Disclosed herein are antibodies capable of inhibiting canine vascular endothelial growth factor and uses thereof in treating a canine angiogenesis-related disorder such as a proliferative disease.

Abstract: A polynucleotide sequence and a method for Ranibizumab cloning, expression and production having better yield and biologically active protein.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.

Abstract: This invention concerns methods of treating a patient diagnosed with a platinum-resistant ovarian cancer comprising administering to said patient an effective amount of an anti-VEGF antibody and a chemotherapeutic.

Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.

Abstract: The present invention provides, among other things, improved anti-CCL2 antibodies characterized with high affinity, potency, tissue selectivity and/or epitope specificity, and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on an anti-CCL2 antibody having an affinity of 10?12M or greater.

Abstract: The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1 modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.

Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.

Abstract: An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.

Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells.

Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Abstract: Provided herein are monovalent antigen-binding constructs targeting EGFR and/or HER2. The monovalent antigen-binding constructs can include at least one antigen-binding polypeptide comprising a heavy chain variable domain, wherein the antigen-bind polypeptide specifically binds EGFR and/or HER2; and a heterodimeric Fc domain, the Fc domain comprising at least two CH3 domains, wherein the Fc domain is coupled, with or without a linker, to the antigen-binding polypeptide. Also provided are methods of making the constructs and methods of using the constructs.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions.

Abstract: Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.

Abstract: The problems: It is an object of the present invention to provide an immune regulating agent capable of modulating a receptor function concerning immune regulation of DR6, and a method for screening thereof. The object aims to provide: The present invention relates to an immune regulating agent containing a physiologically active substance having an ability to bind specifically to DR6 and an ability to regulate signal transduction induced by specific binding between DR6 and Sdc1, as an active component. The immune regulating agent of the present invention can be used for treating or preventing diseases caused by excessive or abnormal immune response in mammals or diseases for which enhancement of immune function is desired in mammals, as an immune regulating agent based on a hitherto unknown mechanism, capable of regulating signal transduction induced by specific binding between DR6 and Sdc1.

Abstract: Provided herein are novel anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.

Abstract: This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

Abstract: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.

Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.

Abstract: The invention relates the use of Human Epidermal Growth Factor Receptor 2 (HER2) gene copy number and HER2 mRNA levels as biomarkers to identify cancers which will respond to treatment with a specific binding member comprising a HER2 antigen binding site engineered into a structural loop region of a constant domain, e.g. CH3 domain, of the specific binding member, and specific binding members which compete with such a binding member for binding to HER2.

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN?LX16X17X18QX20?X21AFIX25X26LWD. The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.

Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.

Abstract: Disclosed herein is an anti-migis-??antibody specific for the migis-? of human m? chain that can bind to mIgA on B lymphocytes, cause the lysis of mIgA-expressing B lymphocytes, and decrease IgA production by IgA-secreting B lymphocytes. Disclosed further is a pharmaceutical composition comprising the anti-migis-? antibody and a pharmaceutically acceptable carrier. Disclosed further is a method for lysing mIgA-expressing B lymphocytes and reducing IgA production in a human subject in vivo by employing an antibody specific for the migis-? of human m? chain that can bind to mIgA on B lymphocytes, cause the lysis of mIgA-expressing B lymphocytes, and decrease IgA production by IgA-secreting B lymphocytes.

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.

Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.

Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.

Abstract: Esterified cellulose ethers comprising groups of formula —C(O)—CHR?—CHR?—COOA, wherein, R? and R? are hydrogen or (—S)m (—R1)n-R2, wherein R1 is a hydrocarbon group having 1 to 4 carbon atoms, R2 is an optionally substituted 5- or 6-membered cyclic group, m and n each independently are 0 or 1, and A is hydrogen or a cation, with the proviso that in each group CHR?—CHR? one of R? and R? is hydrogen and the other one is (—S)m (—R1)n-R?, are useful as excipients for maintaining the concentration of poorly water-soluble drugs in aqueous liquids at supersaturation levels.

Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes. Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.

Abstract: The present invention concerns methods of derivatising sialic acids which may be present on glycan moieties. This can be of use in determining the glycosylation profiles of, for example, glycoproteins and glycolipids and the use of such methods in clinical analysis as well as biological development and control.

Abstract: Provided is a method of purifying polyolefin, the method including the step of contacting linear low-density polyethylene synthesized by a gas phase polymerization reaction with a purge gas containing an ethylene gas and an inert gas in a purge bin. According to this purification method, residual alkene monomers with high carbon numbers may be removed in a simpler and more efficient manner.

Abstract: The present invention relates to a process for the gas-phase polymerisation of olefins in a fluidised bed reactor, which process comprises: a) passing a fluidising gas comprising one or more olefin monomers through a fluidised bed of polymer particles in the presence of a polymerisation catalyst, b) withdrawing a first gaseous stream comprising solid particles from the top of the reactor, c) passing the first gaseous stream to a gas/solids separator, separating solid particles therefrom, and forming a second gaseous stream comprising residual solid particles, d) passing at least a portion of the second gaseous stream to one or more heat exchangers to remove the heat of reaction, and e) recycling at least a portion of the cooled stream from step (d) as the fluidising gas in step (a), characterised in that the rate of fouling of the one or more heat exchangers is such that i) the increase in pressure drop across the heat exchangers is equivalent to less than 5% per year, and/or ii) the decrease in heat transfer

Abstract: Techniques are provided for polymerization. A polymerization method may include polymerizing a monomer in a polymerization reactor to produce a slurry comprising polyolefin particles and a diluent, flowing the slurry out of the polymerization reactor through an outlet of the polymerization reactor, receiving the slurry from the outlet into a slurry handling system, conveying a first mixture from the slurry handling system to a diluent and monomer recovery system, and injecting steam into the first mixture downstream of the slurry handling system using a steam injection system.

Abstract: A styrene based water soluble polymer containing pendant sulfonated calix[4]arene groups has been synthesized by using free radical polymerization combined with post-polymerization sulfonation chemistry. The monomer 25-(4-vinylbenzyl)-26,27,28-hydroxy-calix[4]arene was prepared in 3 steps: (1) reduction of 4-vinyl benzoic acid to the respective alcohol (2) formation of the bromide by the Appel reaction and (3) synthesis of the respective ether by Williamson O-alkylation reaction with calix[4]arene. Polymerization was accomplished by azobisisobutyronitrile (AIBN) initiated free radical polymerization technique. Electro-responsive properties of the sulfonated polymer were studied wherein a response to electrochemical stimulus is observed when guest molecules of methyl viologen are incorporated with polymerized 25-(4-vinylbenzyl)-26,27,28-hydroxy-calix[4]arene.

Abstract: Disclosed herein are methods of making bis(phenol) ligand compounds and transition metal bis(phenolate) compounds. The transition metal bis(phenolate) compounds can be used as components in catalyst systems for the polymerization of olefins.

Abstract: This invention relates to a dicyclopentadiene (DCPD)-based resin functionalized with groups capable of reacting with silica or carbon black for use in high performance tires and a preferred method of preparing the functionalized resin comprising ruthenium-catalyzed ring-opening cross metathesis. The functionalized resin may comprise the reaction product obtained by contacting a polymer comprising units derived from (DCPD) and a vinyl monomer or vinylene monomer in the presence of a metathesis catalyst, wherein the vinyl monomer or vinylene monomer comprises at least one of the following functional groups: a silyl group, a siloxy group, or an alkoxysilyl group. This invention further relates to a tire tread composition comprising the functionalized resin and which exhibits enhanced durability, traction, handling, and extractability properties.

Abstract: The present invention relates to use of certain chain transfer agents to control molecular weight of addition mass polymerization of certain polycycloolefinic monomers. More specifically, the present invention relates to use of a series of substituted bicycloalkenes as chain transfer agents in the addition mass polymerization of a series of functionalized norbornene-type monomers. This invention also relates to compositions containing bicycloalkenes as chain transfer agents in forming “in mold” polycycloolefinic polymers by addition mass polymerization.

Abstract: A method for preparing a functionalized polymer, the method comprising the steps of (i) preparing a halosilane-activated nitrogen heterocycle containing a functional group, (ii) preparing a reactive polymer, and (iii) reacting the reactive polymer with the halosilane-activated nitrogen heterocycle containing a functional group.

Abstract: A method for preparing a functionalized polymer, the method comprising the steps of (i) preparing a halocarbon-activated nitrogen heterocycle containing a functional group, (ii) preparing a reactive polymer, and (iii) reacting the reactive polymer with the halocarbon-activated nitrogen heterocycle containing a functional group.

Abstract: Process for copolymerizing ethylene and esters of vinyl alcohol in the presence of free-radical polymerization initiators at pressures in the range of from 110 MPa to 500 MPa and temperatures in the range of from 100° C. to 350° C. in a continuously operated polymerization apparatus comprising a polymerization reactor and one or more compressors, which compress the monomer mixture fed to the polymerization reactor to the polymerization pressure, wherein the monomer mixture is compressed by a sequence of compression stages in which the compressed gas mixture is cooled after each compression stage and the fraction of the monomer mixture, which is liquid after this cooling, is separated off and returned to the polymerization apparatus in liquid form, and wherein at least a part of the liquid fractions obtained after compressing the monomer mixture in the respective compression stage to a pressure of from 0.2 MPa to 10 MPa is purified before being returned to the polymerization process.

Abstract: A gas-phase process for making a propylene-based polymer in a fluidized-bed reactor, the reactor containing a fluidized bed including polymer product particles and a catalyst, the process having a set of quantitative criteria for maximum monomer partial pressure, maximum reactor temperature, and comonomer content(s) in the propylene-based polymer. The propylene-based polymer may be EBPT or BPRCP. The catalyst may include a catalyst/donor system comprising (1) a supported Ziegler-Natta pro-catalyst, (2) a co-catalyst, and (3) a mixed external electron donor system including (a) an activity limiting agent including at least one carboxylate ester functional group, and (b) a selectivity control agent.

Abstract: Provided are a polyolefin resin having two crystallization temperatures, a resin composition including the polyolefin resin, an encapsulant film, a method for manufacturing the encapsulant for an optoelectronic device, and an optoelectronic device, in which the encapsulant having high light transmittance and low haze value can be provided even under the condition of low lamination, and the resin composition including the polyolefin resin can be used for manufacturing various encapsulants for an optoelectronic device, thereby providing excellent adhesive strength with the front substrate and back sheet included in the device, especially, a long-term adhesion property and improved heat resistance.

Abstract: The present invention relates to a long-chain branched elastic terpolymer capable of satisfying excellent processability and elasticity (flexibility) at the same time, which is obtained in the presence of a Group IV transition metal catalyst, and a preparation method thereof. The elastic terpolymer is a copolymer of ethylene, an alpha-olefin having 3 to 20 carbon atoms, and a diene, wherein i) its weight average molecular weight measured by GPC is 100,000 to 500,000, and ii) x which is the ethylene content (% by weight) and y which is the density value (g/cm3) of the copolymer measured when the ethylene content is X satisfy a relationship of 0.0000175214x(x?75.65420571)+0.875?y?0.0000175214x(x?75.65420571)+0.881.